bremelanotide PT-141 female HSDD
Selected indexed studies
- Medical Treatment of Female Sexual Dysfunction. (Urol Clin North Am, 2022) [PMID:35428435]
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. (J Midwifery Womens Health, 2021) [PMID:34510696]
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire. (Neurol Int, 2022) [PMID:35076581]
_Worker-drafted node — pending editorial review._
Connections
bremelanotide PT-141 female HSDD is a side effect of
Sources
- Medical Treatment of Female Sexual Dysfunction. (2022) pubmed
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. (2021) pubmed
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. (2020) pubmed
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. (2024) pubmed
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire. (2022) pubmed
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. (2022) pubmed
- An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. (2023) pubmed
- Pharmacotherapy for Sexual Dysfunction in Women. (2022) pubmed
- Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. (2019) pubmed
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. (2022) pubmed